Basic Information
| LncRNA/CircRNA Name | MIR17HG |
| Synonyms | MIR17HG, C13orf25, FGLDS2, LINC00048, MIHG1, MIRH1, MIRHG1, NCRNA00048, miR-17-92 |
| Region | GRCh38_13:91347820-91354579 |
| Ensemble | ENSG00000215417 |
| Refseq | NR_027349 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR, RIP, other |
| Sample | CRC tissues and cell lines (HCT15, HCT116, SW480, SW620, HT29, DLD-1, RKO and LoVo) |
| Expression Pattern | up-regulated |
| Function Description | Mechanistically, MIR17HG increased the expression of NF-?B/RELA by competitively sponging the microRNA miR-375. In addition, RELA transcriptionally activated MIR17HG in a positive feedback loop by directly binding to its promoter region. Moreover, miR-17-5p, one of the transcribed miRNAs from MIR17HG, reduced the expression of the tumor suppressor B-cell linker (BLNK), resulting in increased migration and invasion of colorectal cancer cells. MIR17HG also upregulated PD-L1, indicating its potential role in immunotherapy. Overall, these findings demonstrate that MIR17HG plays an oncogenic role in colorectal cancer and may serve as a promising therapeutic target. |
| Pubmed ID | 31409641 |
| Year | 2019 |
| Title | Long Noncoding RNA MIR17HG Promotes Colorectal Cancer Progression via miR-17-5p |
External Links
| Links for MIR17HG | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |